中国药房2024，Vol.35Issue(2)：251-256,6.DOI:10.6039/j.issn.1001-0408.2024.02.23
左乙拉西坦治疗药物监测的研究进展
Research progress in therapy drug monitoring of levetiracetam
摘要
Abstract
Levetiracetam(LEV)is the second generation of broad-spectrum anti-epileptic drug.LEV has the advantages of rapid absorption,short half-life,precise efficacy,good tolerance and few drug interactions.In order to improve the clinical efficacy of LEV,and reduce the occurrence of adverse reactions,children,pregnant women,the elderly,and patients with renal insufficiency should receive therapeutic drug monitoring(TDM).Clinically,the samples are usually plasma or serum,and the TDM methods are mostly immunoassay or chromatography.There is currently no consensus on the effective concentration range of LEV,and the correlation between plasma concentration and adverse reactions is also unclear.The main factors affecting LEV plasma concentration include age,pregnancy,and patient compliance.How to interpret TDM results and adjust dosage based on the results will be the focus of future work.关键词
左乙拉西坦/治疗药物监测/合理用药/血药浓度Key words
levetiracetam/therapeutic drug monitoring/rational drug use/plasma concentration分类
医药卫生引用本文复制引用
高畅,倪斌,陈芳辉,郭春钰,魏桂林..左乙拉西坦治疗药物监测的研究进展[J].中国药房,2024,35(2):251-256,6.基金项目
江西省卫生健康委科技计划项目(No.202130626) （No.202130626）
赣州市指导性科技计划项目(No.GZ2021ZSF040) （No.GZ2021ZSF040）
赣州市卫生健康委员会市级科研计划项目(No.2020-2-89) （No.2020-2-89）
赣南医学院第一附属医院博士启动项目(No.QD074) （No.QD074）
